ClinicalTrials.gg

Program

KAT6 Inhibitor OP-3136

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Olema Pharmaceuticals.

Furthest: phase 1, since Jan 14, 20251 company-led study, 1 open or runningNext primary completion: May 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Olema Pharmaceuticals11 open or runningphase 1since Jan 14, 2025Jan 14, 2025May 30, 2027phase 1 · NCT06784193

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 14, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06784193 · 180 planned · United States, Australia, France and more

Ahead

  1. May 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06784193

TargetBeta

KAT6A →KAT6B →read by rule
“An orally bioavailable inhibitor of histone acetyltransferases KAT6A (MOZ; MYST3) and KAT6B (MORF; MOZ2; MYST4), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
prifetrastatPfizerphase 310
KAT6A/B Inhibitor BG-75202ruleBeOne Medicinesphase 12
HRS-2189Jiangsu HengRui Medicinephase 12
KAT6/KAT7 Inhibitor PF-08032562rulePfizerphase 11
KAT6/KAT7 Inhibitor IDE574ruleideaya-biosciencesphase 11
HLX97Fosun Pharmaphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06784193Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more1RecruitingMay 30, 2027180

How it is read

Names in the registry

  • “OP-3136”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.